Results 131 to 140 of about 4,193,744 (287)
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu +9 more
wiley +1 more source
The Relationship Between Inflammation and Central Nervous System in Multiple Sclerosis
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Aim Multiple sclerosis is an autoimmune demyelination disease that is seen especially in the young population and has a progressive course, causing motor, sensory, and cognitive deficits. In the literature, the pathogenesis of MS disease and the interconnection between the immune and central nervous system in the disease have not been fully ...
Gamze Ansen +5 more
wiley +1 more source
Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways
Cell, 2017 Nicholas W. Bellono +8 more
semanticscholar +1 more source
Soluble NgR Fusion Protein Modulates the Proliferation of Neural Progenitor Cells via the Notch Pathway [PDF]
, 2011 Xin Li +6 more
openalex +1 more source
Portable Low‐Field Magnetic Resonance Imaging in People With Human Immunodeficiency Virus
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective The aging population of people with HIV (PWH) raises heightened concerns regarding accelerated aging and dementia. Portable, low‐field MRI (LF‐MRI) is an innovative technology that could enhance access and facilitate routine monitoring of PWH.
Annabel Sorby‐Adams +14 more
wiley +1 more source
Neural Pathway of Renovative and Innovative Products Appreciation [PDF]
, 2016 Furong Huang, Chi‐yue Chiu, Jing Luo
openalex +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source